0001628280-26-035126
SEC filingQ1 FY2026 losses narrowed significantly year-over-year to -$4.2M net loss and -$4.6M operating loss, driven by R&D cost reductions including lower external services, though collaboration revenue remained minimal at $16K amid ongoing clinical advancement.
Revenue totaled $16K under GAAP, attributable to a BlueRock collaboration option extension, underscoring the pre-revenue status with no approved products or product sales. Management notes the company has not generated revenue from product sales or otherwise historically, aligning with its clinical-stage biotech trajectory.
Other significant costs persist, including legal fees for corporate matters, professional fees for accounting and consulting, insurance, and facility allocations. Despite these quarterly improvements, the company anticipates expenses and operating losses will increase substantially over the foreseeable future, particularly as research and development and manufacturing costs rise with planned preclinical and clinical activities. Net losses and negative cash flows have persisted since inception, with continued expectation of losses ahead.
Liquidity remains a critical focus, as the company's continued existence depends on management's ability to raise capital, collect receivables under agreements, and develop profitable operations. This pre-revenue phase emphasizes the need for funding to support advancing clinical programs while leveraging recent lease restructuring for cost efficiency.